1 Otitis Media Results from the Kaiser Permanente Efficacy Trial Steven Black, MD, Henry Shinefield, MD and Bruce Fireman, MS Kaiser Permanente Vaccine.

Slides:



Advertisements
Similar presentations
University of Minnesota – School of Nursing Spring Research Day Glycemic Control of Critically Ill Patients Lynn Jensen, RN; Jessica Swearingen, BCPS,
Advertisements

Acute Otitis Media Trials: Evolution of Guidance Janice Soreth, M.D. Division of Anti-Infective Drug Products January 30, 2001.
Influenza and Influenza Vaccine
DO HEALTHY CHILDREN NEED TO GET VACCINATED?. Rationale for childhood vaccination Annual influenza vaccine is widely recommended for children at high risk.
Journal Club Usha Niranjan PICU. Rationale 2 x cases of severe dehydration with metabolic acidosis –requesting for HDU management –as given 40mls/kg fluid.
Adoption of an Electronic Medical Record-Based Decision Support Tool for Otitis Media Alexander G. Fiks, MD, MSCE, Peixin Zhang, PhD, A. Russell Localio,
Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure Presented at American College of Cardiology Scientific Sessions.
Pneumococcal Disease and Pneumococcal Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease.
Pneumococcal Disease and Pneumococcal Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease.
1 WORK ON COMPUTERS Winter Semester : List of Topics 1. Medical literature as a resource for evidence based medicine. An overview. 2. Biomedical literature.
Racial and Geographic Variations in the Use of Tympanostomy Tubes in Young Children in the United States Lawrence C. Kleinman, MD, MPH Departments of Health.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Improving Parenting Skills Perrin EC, Sheldrick RC, McMenamy JM, Henson BS, Carter.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Nebulized Hypertonic Saline for Bronchiolitis Florin TA, Shaw KN, Kittick M, Yakscoe.
Carlos G. Grijalva, MD MPH Department of Preventive Medicine Vanderbilt University School of Medicine Nashville, Tennessee.
Vaccines and Related Biological Products Advisory Committee Meeting
Vaccines and Related Biological Products Advisory Committee Presentation on Sanofi Pasteur’s H5N1 Vaccine Andrea N. James, M.D. Senior Medical Officer.
Indication for Otitis Media FDA Vaccine and Related Biologicals Advisory Committee Meeting May 21, 2002 Pneumococcal 7-Valent Conjugate Vaccine (Diphtheria.
Marthe Bryant-Genevier, MD, MPH, MHS
Sarah Struthers, MD March 19, 2015
Adolescent Healthcare Utilization in the U.S. Cynthia Rand, MD, MPH University of Rochester School of Medicine and Dentistry.
The Variations and Deviations in the Use of Tympanostomy Tubes for Children with Otitis Media Salomeh Keyhani MD MPH Lawrence C. Kleinman MD MPH Michael.
Effects of Pediatric Asthma Education on Hospitalizations and Emergency Department Visits: A Meta-Analysis June 3, 2007 Janet M. Coffman, PhD, Michael.
Early Parental Satisfaction with Pediatric Care: Does it Improve Immunization of Young Children? Ashley Schempf BS, Cynthia Minkovitz MD MPP Donna Strobino.
State Affiliate Challenge 1 South Dakota School Nurses Association Florida Association of School Nurses Delaware School Nurse Association.
Efficacy and safety of moxifloxacin in patients with secondary peritonitis Post-hoc pooled analysis of 4 prospective multi-centre phase III RCTs in adult.
Probiotics May Lower Risk for Nosocomial Infections in Hospitalized Children A randomized, double-blind, placebo-controlled trial reported in the May issue.
Development of Antibiotics for Otitis Media: Past, Present, and Future Janice Soreth, M.D. Director Division of Anti-Infective Drug Products.
Augmentin ES  for acute otitis media Mamodikoe Makhene, M.D. Prepared for Anti-infectives Advisory Committee meeting January 30, 2001.
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Created byInformation Design A Mathematical Model for the Impact of the Conjugate Vaccine on S. pneumoniae Vaccine and Non-vaccine serotypes Robertino.
Incidence of hospitalisations in both groups Incidence of documented infections Abstract Problem statement: Patients on cancer chemotherapy are at substantial.
FinOM Efficacy Trial of 7-Valent Pneumococcal Conjugate Vaccine Terhi Kilpi National Public Health Institute (KTL) Finland.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Probiotic in Colic, Regurgitation, & Constipation Indrio F, Di Mauro A, Riezzo G,
Giebink – FDA – 07/11/02 Design Issues in Antimicrobial Treatment Trials of AOM G. Scott Giebink, M.D. Professor of Pediatrics and Otolaryngology Director,
1 Vaccines and Related Biological Products Advisory Committee Meeting November 18, 2009 Questions for the Committee Prevnar 13 Pneumococcal 13-valent Conjugate.
1 Vaccines and Related Biologic Products Advisory Committee (VRBPAC) May 16, 2007 FluMist ® Influenza Virus Vaccine Live, Intranasal Safety and Effectiveness.
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
Vaccines and Related Biological Products Advisory Committee (VRBPAC) May 21, 2002 Prevnar™, Pneumococcal Conjugate Vaccine 7-valent, for the Prevention.
N Engl J Med 2010; 362: January 28, 2010 Presenters ; Dr Ngwenya/Dr Nchimba.
Indiaclen Short course of Amoxicillin in treatment of Pneumonia (ISCAP) 3 versus 5 days amoxicillin for treatment of non-severe pneumonia in young children:
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Fundoplication at the Time of Gastrostomy Barnhart DC, Hall M, Mahant S, et al. Effectiveness.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Intermittent vs Continuous Pulse Oximetry McCulloh R, Koster M, Ralston S, et al.
Acute Otitis Media: Lessons Learned Thomas Smith, M.D. Division of Anti-Infective Drug Products.
EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.
Circulatory System Devices Panel Questions for Discussion EMBOL·X Aortic Filter October 23, 2002.
Revising the Decision Analysis For Febrile Children At Risk For Occult Bacteremia In a Future Era of Widespread Pneumococcal Immunization Loren G. Yamamoto,
Safety, Efficacy and Duration of Effect of RT002, a Botulinum Toxin Type A for Injection, to Treat Glabellar Lines: The Phase 2 BELMONT Study Authors:
LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,
Pneumococcal Vaccine Use Around the World: Successes and Challenges Adam L. Cohen, MD MPH Respiratory Diseases Branch, Division of Bacterial Diseases Centers.
Reach Out and Read Fresno: Ongoing benefits in early literacy practices among underserved families Lydia Herrera-Mata, MD Susan Hughes, MS April 27, 2012.
1 13-valent pneumococcal conjugate vaccine (PCV13) – new ACIP recommendations 44 th National Immunization Conference April 21, 2010 Pekka Nuorti, MD, DSc.
A pilot randomized controlled trial Registry #: NCT
R1 강민혜 / prof. 전숙. Introduction Patients with type 2 diabetes have a greatly increased risk of cardiovascular events. The morbidity and mortality related.
C. Jillian Tsai, Ph.D. Department of Preventive Medicine
Date of download: 7/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Immunogenicity of 13-Valent Pneumococcal Conjugate.
Evaluation of the 2004 pneumococcal conjugate vaccine shortage utilizing data from the Michigan Childhood Immunization Registry Norma Allred, PhD, John.
The early use of Antibiotics in at Risk CHildren with InfluEnza Medical notes review
Rosenfeld R, Sajisevi M, Schulz K, CyrD, Wojdyla D, Tucci D, Witsell D
Burden of acute otitis media, recurrent otitis media and tympanostomy tube insertion in urban, minority children less than 7 years of age in Boston: Comparison.
Acute Mastoiditis in the Pneumococcal Conjugate Vaccines Era
Haemophilus influenzae type b Using vaccines to measure disease burden: A Tale of Two Studies Presentation to PABIO 550 Diseases of Public Health Importance.
EMPHASIS-HF Extended Follow-up
Impact of a Telephone Intervention to Increase Pneumococcal Vaccination Rate in a Managed Care Population.
RJ Jacobs AS Meyerhoff Capitol Outcomes Research, Inc.
The Research Question Otitis media with effusion (OME) is the main cause of hearing loss and the commonest reason to have an operation requiring anesthesia.
The laws of acute otitis media
Craig Conlon MD, PhD, Employee Health Services Northern California
Main inclusion criteria)
Chest Pain Choice Trial design: Patients presenting to the ED with low risk chest pain were randomized to either use of a tailored decision aid or routine.
FIGURE 1. Flowchart of PnCRM7 clinical trial participants, primary efficacy cohort, and sub-populations used for efficacy analyses. Clinical trial participants.
Presentation transcript:

1 Otitis Media Results from the Kaiser Permanente Efficacy Trial Steven Black, MD, Henry Shinefield, MD and Bruce Fireman, MS Kaiser Permanente Vaccine Study Center Oakland, California

2 Kaiser Permanente Efficacy Trial Study Design Randomized, double-blind, controlled –7VPnC vs Control (MnCC conjugate) 1:1 Immunizations at 2, 4, & 6 months of age with a booster months –Given concomitantly with routine childhood vaccines Trial began in October 1995 and was unblinded in April 1999

3 Kaiser Permanente Efficacy Trial Otitis Media Outcomes Otitis media diagnoses captured as part of routine care for visits to pediatricians, emergency physicians and specialists; no cross training of observers Surgery for ear tube placement captured as part of hospital database Spontaneously draining ears cultured

4 Primary endpoint: All OM episodes Episode defined as a clinic visit for OM with no prior visit for OM within 21 days Kaiser Permanente Efficacy Trial Otitis Media Primary Endpoint

5 Secondary endpoints: –First otitis episode –Frequent otitis media* –Tympanostomy tube placement –Spontaneously ruptured ear drum due to vaccine serotypes –All clinic visits for otitis media Kaiser Permanente Efficacy Trial Otitis Media Secondary Endpoints *  3 episodes within 6 months or  4 episodes within 12 months

6 Clinical Episodes OM Bacterial OM Pneumococcal OM Vaccine Serotype OM Otitis Media: A Frame of Reference % % % Overall potential impact = % if 100% efficacy

7 Follow-up for Otitis Media OM data cutoff for original submission April 30, 1998 Blinded immunization per protocol continued Study nurses, physicians and parents unblinded April 20, 1999 – 37,868 children randomized

8 Study Population for Otitis Media April 1998 and April 1999 April 1998 DatabaseApril 1999 Database Number of children 7vPnC Control Number of children 7vPnC Control Total Enrolled17,06617,08018,92618,942 Booster: Dose 49,0479,12216,12216,152 Age> 2 yrs at end of per-protocol follow-up 2,7352,7707,2667,320 Age> 3 yrs at end of per-protocol follow-up 002,3272,319

9 Otitis Media Events *  3 episodes within 6 months or  4 episodes within 12 months

10

11

12 *First Procedure

13

14 Overall Number of Oral Antibiotic Prescriptions As of April 20, 1999

15 Otitis Media Conclusions Prevnar significantly reduced the risk of otitis media Efficacy was higher for frequent otitis and for ear tube placement

16 Thank you